The Reagents, Kits, and Services Store offers an extensive selection of pre-developed and qualified consumables, samples, protocols, and tailored services for custom biochemistry and experimental design. The portfolio includes a variety of products for DNA, RNA, and protein folding assays, eliminating the need for users to invest money, time, and personnel in setting up experimental workflows.
The script-sharing platform Harbor is a free, open-access portal where users can publish, download, review, and cite scripts that automate DSM experiments and analyze extracted data. Elements, such as the build-in citation section and interaction indicators (likes, downloads, comments), are used by both novice and expert users to review scripts, cite them, and highlight golden standard methods. These scripts run directly within the control software of LUMICKS instruments.
“This is a major step forward in broadly unlocking Dynamic Single-Molecule analysis to the broader biology community,” said Olivier Heyning, CEO at LUMICKS. “With our reagents and kits, users can get started with meaningful experiments in a matter of days. With the Harbor platform, we took the strategic choice to closely collaborate with our user community to break the barriers by establishing and continuously improving the informatics toolbox for single-molecule experiments and analysis. This makes DSM research accessible to all types of users, regardless of experience level and scientific focus area.”
For more information, visit harbor.lumicks.com and store.lumicks.com.
LUMICKS is a leading life sciences company that develops equipment for dynamic single-molecule and cell avidity analysis, two emerging areas in biology research and immuno-oncology (IO). Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018), STED super-resolution (Nobel Prize for Chemistry 2014), and acoustic force spectroscopy, LUMICKS tools facilitate the understanding of life to the smallest detail. Applying and measuring forces in biology enables real-time analysis of true biological mechanisms. This creates the crucial and yet unexplored bridge between structure and function at the molecular and cellular level. The latest technology in the company’s arsenal, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells. This technology is game-changing for the development and application of IO therapies for the treatment of cancer.
For more information contact:
Name: Olivier Heyning, CEO
Phone: +31 (0) 20 220 08 17
Name: Kassandra Barbetsea, PR & Marketing
Phone: +31 (0) 63 482 09 48
Company: LUMICKS B.V.